CD33 Inhibition for Reducing Beta Amyloid Accumulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current understanding of late-onset Alzheimer's disease (LOAD) mechanisms is incomplete, and existing therapies are inadequate in addressing beta amyloid accumulation, which is a central pathogenic mechanism in the disease.
Innovation Solution
Inhibiting the CD33 protein, either by reducing its expression or activity, to decrease beta amyloid accumulation in microglial cells, which are shown to be involved in the uptake and clearance of beta amyloid, thereby mitigating Aβ pathology.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If CD33 protein is present and active in microglial cells, then microglial cells can perform their normal immune function, but beta amyloid accumulation increases leading to neurodegeneration
Solution Approach 1:
The patent applies this principle by converting the harmful effect of CD33 (which promotes beta amyloid accumulation and neurodegeneration) into a beneficial therapeutic target. By identifying CD33 as the harmful factor, the invention develops inhibitors that block CD33 function, thereby converting the pathological process into a treatable condition. The CD33 inhibitor transforms the disease mechanism into a therapeutic opportunity by specifically targeting the protein responsible for harmful amyloid accumulation while preserving normal microglial functions.
2Object-generated harmful factors
If CD33 inhibitor is administered to decrease beta amyloid accumulation, then amyloid plaque burden is reduced, but potential off-target effects on microglial function may occur
Solution Approach 1:
The patent applies this principle by using CD33 as an intermediary target that mediates between beta amyloid accumulation and microglial function. The CD33 inhibitor selectively blocks the pathological role of CD33 in promoting amyloid accumulation while allowing normal microglial immune functions to continue. This intermediary approach enables therapeutic intervention at a specific point in the disease pathway without completely disrupting microglial physiology.
3Ease of operation
If existing Alzheimer's disease therapies are used, then some symptomatic relief may be achieved, but beta amyloid accumulation is not adequately addressed
Solution Approach 1:
The patent applies this principle by extracting and specifically targeting the root cause of Alzheimer's disease (beta amyloid accumulation mediated by CD33) rather than treating only the symptoms. The CD33 inhibitor removes the pathological mechanism of amyloid accumulation from the disease system, addressing the fundamental problem that existing therapies fail to tackle. This extraction approach separates the therapeutic action from symptomatic management and directly eliminates the harmful accumulation process.
Data Source
AI summary
The present disclosure provides compositions and methods useful for treating or preventing diseases or disorders where beta amyloid accumulation or aggregation contributes to the pathology or symptomology of the disease, for example Alzheimer's disease.